Sanofi Labels Biosimilars 'Enormous Distraction'

French Player Has A Small Biosimilar Presence

While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.

Insulin pen
Sanofi exited diabetes research last year but kept hold of a biosimilar insulin aspart candidate • Source: Shutterstock

Sanofi’s global head of research and development, John Reed, has described biosimilars as an “enormous distraction” for a company pursuing novel therapies.

While several Big Pharma companies have over the last decade enjoyed successes juggling a biosimilars unit with a much larger...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.